Literature DB >> 9331201

Adenoid cystic carcinomas of the lacrimal gland in childhood and adolescence.

M V Tellado1, I W McLean, C S Specht, J Varga.   

Abstract

OBJECTIVE: To see if there is a correlation between histologic features of these tumors and final outcome.
DESIGN: A small series of cases of adenoid cystic carcinomas of the lacrimal gland in patients 18 years of age or younger were evaluated. PARTICIPANTS: A total of 11 cases of adenoid cystic carcinoma of the lacrimal gland in patients 18 years of age or younger found in the registry of Ophthalmic Pathology at the Armed Forces Institute of Pathology were studied. INTERVENTION: Histologic material obtained by excision of lacrimal gland tumors was evaluated for different morphologic parameters. Clinical follow-up information was reviewed. MAIN OUTCOME MEASURES: All cases were evaluated for proportion of a basaloid histologic pattern: necrosis, hemorrhage, mitotic count, and perineural, vascular, intraosseous, leptomeningeal, and optic nerve invasion. These parameters were examined for an association with the clinical follow-up that was obtained for eight of the patients (mean follow-up, 10 years; range, 2-14 years).
RESULTS: Most of the patients were female (M:F = 2:9). Mean age was 14 years (range, 6.5-18 years). Of the patients with follow-up, 5 (62.5%) of 8 survived. Estimated survival rate at 15 years was 58% (Kaplan-Meier analysis). Survivors had 25% or less basaloid histology. Necrosis, hemorrhage, perineural invasion, and mitotic count were less prominent in survivors than in those who died of disease. Vascular invasion was seen only in fatal cases.
CONCLUSIONS: Young patients with adenoid cystic carcinomas have a better prognosis than do adult patients, which may be due to their tumors having less aggressive histologic features.

Entities:  

Mesh:

Year:  1997        PMID: 9331201     DOI: 10.1016/s0161-6420(97)30086-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma.

Authors:  David T Tse
Journal:  Trans Am Ophthalmol Soc       Date:  2005

Review 2.  Cervical lymph node metastasis in adenoid cystic carcinoma of the sinonasal tract, nasopharynx, lacrimal glands and external auditory canal: a collective international review.

Authors: 
Journal:  J Laryngol Otol       Date:  2016-11-14       Impact factor: 1.469

3.  Expression of apoptosis-related markers in malignant epithelial tumours of the lacrimal gland and their relation to clinical outcome.

Authors:  Diego Strianese; Gianluca Baldi; Stefania Staibano; Alfonso Baldi; Gaetano De Rosa; Fausto Tranfa; Giulio Bonavolontà
Journal:  Br J Ophthalmol       Date:  2007-04-12       Impact factor: 4.638

4.  Lacrimal gland tumors in Turkey: types, frequency, and outcomes.

Authors:  Yağmur Seda Yeşiltaş; Ahmet Kaan Gündüz; Esra Erden; Carol L Shields
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

5.  Adenoid cystic carcinoma of the lacrimal gland.

Authors:  Vasantha Thavaraj; M R Sridhar; A Sethi; L S Arya
Journal:  Indian J Pediatr       Date:  2003-09       Impact factor: 1.967

6.  Outcomes in patients with lacrimal gland carcinoma treated with definitive radiotherapy or eye-sparing surgery followed by adjuvant radiotherapy.

Authors:  Yun-Hsuan Lin; Shih-Ming Huang; Wing-Keen Yap; Ju-Wen Yang; Ling Yeung; Din-Li Tsan; Joseph Tung-Chieh Chang; Lung-Chien Chen
Journal:  Radiat Oncol       Date:  2020-06-22       Impact factor: 3.481

7.  Multimodal therapy in the management of lacrimal gland adenoid cystic carcinoma.

Authors:  Jie Yang; Chuandi Zhou; Yefei Wang; Xianqun Fan; Renbing Jia
Journal:  BMC Ophthalmol       Date:  2019-06-08       Impact factor: 2.209

8.  miR-93-5p enhance lacrimal gland adenoid cystic carcinoma cell tumorigenesis by targeting BRMS1L.

Authors:  Jie Hao; Xin Jin; Yan Shi; Hong Zhang
Journal:  Cancer Cell Int       Date:  2018-05-09       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.